Purpose:To evaluate and report the short-term anatomical effects of switching from bevacizumab to the ranibizumab biosimilar CKD-701 in patients undergoing treatment for neovascular age-related macular degeneration (AMD).

Methods:A retrospective medical record analysis was conducted on patients receiving bevacizumab therapy for neovascular AMD who were subsequently switched to CKD-701. The changes in central macular thickness and frequency of intraretinal/subretinal fluid before and after a single CKD-701 injection were compared with those before and after a single bevacizumab injection.

Results:A total of 20 eyes was included in the study. Following bevacizumab injection, the mean central macular thickness decreased by 14.9 ± 57.6 µm, with intraretinal and subretinal fluid observed in 75.0%/55.0% before injection and 60.0%/55.5% after injection, respectively. Following CKD-701 injection, the mean central macular thickness decreased by 34.9 ± 57.4 µm, with intraretinal and subretinal fluid observed in 75.0%/56.0% before injection and 45.0%/40.0% after injection, respectively. There were no significant differences between the two groups in terms of changes in central macular thickness (p = 0.204), frequency of intraretinal fluid (p = 1.000), and subretinal fluid (p = 0.748) observed before injection or in frequency of intraretinal fluid (p = 0.527) and subretinal fluid (p = 0.527) after injection.

Conclusions:The short-term anatomical outcomes following CKD-701 injection in neovascular age-related macular degeneration showed no significant difference compared to the short-term outcomes following bevacizumab injection previously administered.